| scholarly article | Q13442814 |
| P50 | author | Ingvar Hjermann | Q17096773 |
| P2093 | author name string | I. Holme | |
| A. Helgeland | |||
| P. Leren | |||
| P. G. Lund-Larsen | |||
| P. O. Foss | |||
| P2860 | cites work | Metabolic effects of beta-adrenoreceptor blockers | Q39097108 |
| Effect of chronic administration of propranolol on lipoprotein composition | Q40016405 | ||
| The Oslo study. Cardiovascular disease in middle-aged and young Oslo men | Q45252765 | ||
| Beta-blockers and plasma triglycerides. | Q55145583 | ||
| High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study | Q55716990 | ||
| Beta-blockers and lipid metabolism | Q66701578 | ||
| A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators | Q66890716 | ||
| P433 | issue | 8184 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipid | Q11367 |
| P304 | page(s) | 4-6 | |
| P577 | publication date | 1980-07-01 | |
| 1980-07-05 | |||
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Effect of propranolol and prazosin on blood lipids. The Oslo Study | |
| P478 | volume | 2 |
| Q50572102 | A randomized controlled trial of the effects of aerobic dance training on blood lipids among individuals with hypertension on a thiazide. |
| Q69666950 | Adrenergic blocking agents and lipoprotein lipase activity |
| Q72565860 | Adrenergic control of lipid metabolism |
| Q34750825 | Adrenergic mechanisms in control of plasma lipid concentrations |
| Q72574919 | Adrenergic mechanisms in the control of plasma lipids in man |
| Q40096624 | Alpha- and beta-blockade in angina pectoris. |
| Q34450268 | Antihypertensive drugs and blood lipids: the Oslo study |
| Q40621879 | Antihypertensive drugs: issues beyond blood pressure control |
| Q70243657 | Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension |
| Q71792137 | Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects |
| Q34550182 | Beta adrenoceptor blockade and responses of serum lipids to a meal and to exercise |
| Q72591105 | Beta-blocker induced changes in the cholesterol: High-density lipoprotein cholesterol ratio and risk of coronary heart disease |
| Q34621078 | Changes in blood chemistry in hypertensive patients during propranolol therapy |
| Q36972766 | Choosing the Optimum Therapy for Older Hypertensive Patients |
| Q36482914 | Clinical perspective on celiprolol: Cardioprotective potential |
| Q37592754 | Clinical use of beta-adrenoceptor blockade in systemic hypertension |
| Q42156299 | Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension |
| Q36488713 | Comparative study of the effects of prazosin and atenolol on plasma lipids of hypertensive patients |
| Q72574916 | Comparison of in vitro and in vivo effects of prazosin on lipid metabolism |
| Q68211592 | Comparison of nicardipine and propranolol in the treatment of mild and moderate hypertension |
| Q35646020 | Continuous positive airway pressure treatment: effect on serum lipids in patients with obstructive sleep apnoea |
| Q70245152 | Controversies in hypertension: Mild hypertension, isolated systolic hypertension, and the choice of a step one drug |
| Q40087301 | Diuretics or ??-Blockers First for Hypertension? |
| Q34446855 | Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins |
| Q55062518 | Double-blind comparison of trimazosin and propranolol in essential hypertension |
| Q39469038 | Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension |
| Q77452765 | Drugs causing dyslipoproteinemia |
| Q71081499 | Effect of L-propranolol on the binding, internalization and degradation of 125I-low density lipoproteins by human skin fibroblasts |
| Q40093360 | Effect of alpha- and beta-blocker therapy on blood lipids: European experience |
| Q72547675 | Effect of antihypertensive agents on lipid metabolism |
| Q67763370 | Effect of lacidipine, a long-acting calcium antagonist, on hypertension and lipids: a 1 year follow-up |
| Q34782550 | Effect of long-term treatment with beta-blocking drugs on plasma lipids and lipoproteins |
| Q51643750 | Effect of oxprenolol and metoprolol on serum lipid concentration. |
| Q69426446 | Effect of pindolol on changes in serum lipids induced by hydrochlorthiazide |
| Q70298199 | Effect of trimazosin on serum lipid profiles in hypertensive patients |
| Q33172949 | Effectiveness of prazosin as initial antihypertensive therapy |
| Q72536831 | Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension |
| Q72574912 | Effects of alpha- and beta-blocker antihypertensive therapy on blood lipids: A multicenter trial |
| Q70329857 | Effects of antihypertensive therapy on plasma lipids and lipoproteins in the multiple risk factor intervention trial |
| Q72561725 | Effects of indapamide and various diuretics alone or combined with beta-blockers on serum lipoproteins |
| Q70329851 | Effects of long-term prazosin therapy on lipoprotein metabolism in hypertensive patients |
| Q57224194 | Effects of pindolol and propranolol on blood lipids in hypertensive patients |
| Q69908546 | Effects of prazosin and alphamethyldopa on blood lipids and lipoproteins in hypertensive patients |
| Q40093049 | Effects of prazosin on serum lipids in patients with essential hypertension: A review of the findings presented at the satellite symposium on coronary heart disease: Hypertension and other risk factors, Milan, 1983 |
| Q36750058 | Effects of short term beta adrenoreceptor blockade on serum lipids and lipoproteins in patients with hypertension or coronary artery disease |
| Q42620274 | Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol |
| Q42201566 | Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway |
| Q73724870 | Failure of the nonselective beta-blocker propranolol to affect lipoprotein lipase gene expression in the rat |
| Q34450353 | HDL cholesterol and beta-adrenoceptor blocking agents in a 5 year multifactorial primary prevention trial |
| Q40093973 | Identification of patients who do not require beta antagonists after myocardial infarction |
| Q43260485 | Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol |
| Q72707779 | Increased β-Thromboglobulin in Essential Hypertension: Interactions between Arterial Plasma Adrenaline, Platelet Function and Blood Lipids |
| Q40862415 | Insulin resistance syndrome: possible key role of blood flow in resting muscle |
| Q40092094 | Intrinsic sympathomimetic activity: Clinical fact or fiction? |
| Q38216087 | Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy |
| Q72586914 | Mental health and hypertension |
| Q68065229 | Metabolic effects of carteolol and dilevalol in essential hypertension |
| Q34446862 | Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension |
| Q70298320 | Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension |
| Q70243849 | Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: Possible alternative drug therapies |
| Q71674895 | New approaches to the therapy of mild hypertension |
| Q72554844 | New choices for the initial drug therapy of hypertension |
| Q69922255 | Nonselective beta-receptor blocker effect on high density lipoprotein cholesterol after chronic exercise |
| Q69882989 | Oslo Hypertension Study |
| Q38809851 | Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis |
| Q69126606 | Pharmacological treatment of lipid disorders in diabetes mellitus |
| Q40087513 | Pindolol-a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations |
| Q72533813 | Plasma Lipids and Lipoproteins in Long-Term Beta-Adrenergic Blockade |
| Q35954157 | Plasma apolipoproteins and lipids in normal persons and patients with hypertension |
| Q34620789 | Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients |
| Q40135068 | Prazosin Update A Review of its Pharmacological Properties and Therapeutic Use in Hypertension and Congestive Heart Failure |
| Q39631858 | Recent issues in antihypertensive drug therapy |
| Q36716618 | Regression of Increased Left Ventricular Mass by Antihypertensives |
| Q61456032 | Relación entre el perfil de riesgo cardiovascular y la selección y utilización de los fármacos antihipertensivos |
| Q40847980 | Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes |
| Q72523147 | Reversal or prevention of diuretic-induced alterations in serum lipoproteins with betablockers |
| Q40977152 | Risk and management of hypertension-related left ventricular hypertrophy |
| Q69883586 | Secondary prevention after myocardial infarction |
| Q33684914 | Serum lipids and glucose concentrations in subjects using antihypertensive drugs: Finnmark 1977. |
| Q69056925 | Serum lipids and lipoproteins in ischaemic heart disease following withdrawal of long-term metoprolol treatment |
| Q70940690 | Serum lipoprotein changes during atenolol treatment of essential hypertension |
| Q68934275 | Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial |
| Q72582366 | Short-term versus long-term changes in serum cholesterol with thiazide diuretics alone |
| Q33814337 | Survival in treated hypertension: follow up study after two decades |
| Q51648724 | The Effect of Spironolactone on Lipid, Glucose and Uric Acid Levels in Blood during Long-Term Administration to Hypertensives |
| Q39463801 | The adrenergic inhibitors. |
| Q71965040 | The effects of a selective Alpha-1 adrenergic blockade on the activity of adipose tissue lipoprotein lipase in female hamsters |
| Q39460803 | The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs |
| Q39464499 | The effects of beta-adrenergic blocking agents on blood lipid levels |
| Q34194119 | The effects of diuretics and adrenergic-blocking agents on plasma lipids |
| Q68687373 | The effects of prazosin and propranolol in combination with thiazide diuretics on blood pressure and serum lipids: a multicentre study |
| Q36706547 | The effects of treatment on target organ damage in hypertensive disease |
| Q40164538 | The influence of hypertension and other hemodynamic factors in atherogenesis |
| Q41341811 | The pharmacological basis for the use of alpha 1-adrenoceptor antagonists in the treatment of essential hypertension |
| Q68712510 | The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants |
| Q40094755 | The use of β-adrenergic blocking drugs in patients with myocardial infarction |
| Q41171807 | Therapeutic challenges in the obese diabetic patient with hypertension |
| Q69617277 | Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. WHO Drug Utilization Research Group (DURG) |
| Q37581206 | Treating hypertension and cardiovascular risk: are there trade-offs? |
| Q72547679 | Treating the patient with mild hypertension and renal insufficiency |
| Q39666927 | Vascular changes in hypertension |
| Q93852164 | Vitamin D and the lymphomedullary system |
| Q40089857 | Which beta blocker? |
| Q68165788 | Withdrawal of chronic beta-adrenoceptorblockade: effects on haemodynamics, blood lipids and haemostatic variables |
| Q69868397 | Working ability and exercise tolerance during treatment of a mild hypertension. I. Comparison between a beta-adreno-receptor blocking drug and a calcium antagonist |
| Q42225332 | Working ability and exercise tolerance during treatment of mild hypertension. II. A comparison between atenolol and prazosin medication |
| Q54519758 | [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)]. |
| Q72577818 | [Antihypertensive therapy and lipid metabolism] |
| Q40093200 | β-Adrenergic Blockade for Survivors of Acute Myocardial Infarction |
Search more.